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Abstract: 
 
Major group HRVs bind intercellular adhesion molecule 1 (ICAM1) and minor group HRVs 
bind members of the low-density lipoprotein receptor (LDLR) family for cell entry. Whereas 
the former share common sequence motives in their capsid proteins, in the latter only a lysine 
residue within the binding epitope in VP1 is conserved; this lysine is also present in ten "K-
type" major group HRVs which fail to bind LDLR.                                                                    
A bioinformatic approach based on the available VP1 sequences three-dimensional models of 
VP1 of all HRVs were built and binding energies, with respect to module 3 of the very-low 
density lipoprotein receptor, were calculated. Based on the predicted affinities, K-type HRVs 
and minor group HRVs were correctly classified. With the intention to find conserved binding 
patterns the energy tables that indicate the interacting binding partners were transformed into 
heatmaps. In addition to the heatmaps a bar diagram that shows the interaction energy of the 
different receptor residues of all minor group and K-type viruses was made. In further 
improvements the module 3 of VLDLR was replaced by the ligand binding repeat 5 of human 
and mouse LDLR.  To examine the predictive power of the in silico application two non-
classified field isolates were analyzed. In a site directed mutagenesis experiment the HI-loop 
of HRV14 (major group) was changed into the sequence of the HI-loop of HRV2 (minor 
group). The newly created chimeric virus (HRV14_HI2) was not infective. Also a revision of 
the experiments under optimized conditions could not create an infective virus. The only 
chimeric virus that could be produced was HRV14_K. In this virus a histidine to lysine 
mutation at position 232 was successfully accomplished. The properties of this artificial K-
Type virus to bind LDLR were checked in infection assays using RD cells. 
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Zusammenfassung: 
 
Humane Rhinoviren (HRV) sind verantwortlich für  rund die Hälfte aller Erkältungen beim 
Menschen. Die zur Familie der Picornaviren gehörigen Rhinoviren besitzen ein 
ikosaedrisches Kapsid, das aus den 4 viralen Strukturproteinen (VP1, VP2, VP3 und VP4) 
aufgebaut ist. Der Durchmesser dieses Kapsids beträgt 30 nm. Die mehr als hundert 
verschiedenen Virustypen können anhand ihrer Fähigkeit an zelluläre Rezeptoren zu binden 
eingeteilt werden. Die weitaus größere Gruppe der beschriebenen Rhinoviren binden an den 
ICAM-1 Rezeptor um in die Wirtszelle zu gelangen. Eine kleine Gruppe von Rhinoviren, 
genannt „minor group“ Viren binden an LDL-Rezeptoren, wie LDLR, LRP und VLDLR. Ein 
Ziel dieser Arbeit war es neue Einblicke in die Details der Interaktion von Virus und Rezeptor 
zu erhalten. Vorhergehende Untersuchungen dieser Interaktion zeigten, dass nur ein virales 
Protein in diese Wechselwirkung involviert ist. Dieses virale Protein 1 (VP1 genannt), und im 
speziellen die Oberflächen-„loops“ sind an der Wechselwirkung mit den LDL Rezeptoren 
beteiligt. Sequenzanalysen der LDLR bindenden Rhinoviren („minor group“ viruses) zeigten, 
dass lediglich ein Aminosäurerest, ein Lysin, strikt konserviert ist. Dieses Lysin befindet sich 
in der Mitte des HI-„loop“. Man nahm an, dass dieses Lysin verantwortlich sei für die 
Bindung an LDL Rezeptoren. Es wurden jedoch einige Rhinovirus Typen gefunden, die an 
der gleichen Stelle ebenfalls ein Lysin aufweisen. Diese Gruppe von Viren (K-Typen) können 
anhand ihrer Sequenzmerkmale nicht von „minor group“ Viren unterschieden werden, jedoch 
können sie den LDL Rezeptor nicht für die Infektion verwenden.   
Im ersten Teil meiner Diplomarbeit ging es um die Entwicklung eines Bioinformatischen 
Klassifizierungsverfahrens. Mit diesem sollte es möglich sein alle bekannten Rhinovirus 
Typen gemäß ihrer Rezeptor Spezifikation einzuteilen. Die Methode beruht auf der 
Hypothese, dass bindende Typen eine zum Rezeptor komplementäre Ladungsverteilung an 
ihrer Oberfläche aufweisen, die es ihnen ermöglicht den Rezeptor zu binden. Gemäß dieser 
Hypothese sollten die Bindungsaffinitäten der bindenden Typen höher sein als die der nicht 
bindenden Typen. Die 3D Strukturen des VP1 Proteins wurden durch „homology modelling“ 
erhalten. 3D Koordinaten, die der determinierten Röntgenstruktur von HRV2 mit gebundenen 
V3 entnommen wurden, dienten als Matrize für alle die Anordnung aller anderen Rhinoviren-
Rezeptor Komplexe.  Nach einem Energie Minimisierungsschritt wurden die Modelle aller 
Rhinoviren mit gebundenem Rezeptor hinsichtlich ihrer Bindungsaffinität analysiert.  Eine 
der verwendeten Methoden, war tatsächlich in der Lage alle Rhinoviren korrekt zu 
klassifizieren. Die Gruppe der K-Typen hatten generell höhere Affinitäten zu dem 
verwendeten Rezeptor (V3), als andere „major group“ Viren.  
Im anschließenden Teil der Arbeit wurde ein „major group“ Virus (HRV14) so mutiert, das er 
einen gänzlich veränderten HI-loop aufweist. Die Sequenz des am stärksten in der Virus-
Rezeptor Interaktion involvierten Oberflächen“loop“ (HI-loop) wurde gegen die Sequenz 
eines „minor group“ Virus mittels Zielgerichteter Mutagenese ausgetauscht. RNA Klone der 
mutierten Sequenz waren jedoch nicht infektiös. Es gelang lediglich einen infektiösen Klon 
der nur eine Punktmutation im HI-„loop“ aufwies herzustellen.  
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1.Introduction 
Picornaviruses 
 
Members of the family Picornaviridae (pico=small ) share icosahedral structural symmetry 
and a genome of single-stranded RNA of positive sense. Because of the positive polarity the 
RNA can directly be used as template for synthesis of all the viral proteins required for viral 
replication, and thus picornavirus RNA is infectious. The first infectious cDNA clone of a 
RNA virus was that of poliovirus [1]. Generally, picornaviruses have played an important role 
in modern virology. All members of this family lack a lipid envelope and are therefore 
resistant to ether, chloroform and alcohol. Within this family we can find some important 
human and animal pathogens, including poliovirus, hepatitis A, rhinovirus and FMDV (food 
and mouth disease virus). 
Classification of Picornaviruses 
 
The family Picornaviridae belongs to the order Picornavirales and consists of 8 genera: 
Enterovirus, Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, Kobuvirus and 
Teschovirus, plus three proposed genera named "Sapelovirus", "Senecavirus" and 
"Tremovirus". (Fig.1)  
 
Figure 1: Unrooted neighbor-joining tree of Picornaviridae based on a comparison of the P1 capsid region. 
(http://www.picornastudygroup.com/posters/psg_posters.htm) 
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A list of important members of the picornavirus family can be seen in Table 1. Five of the 
picornaviridae genera contain human pathogens.  
 
 
Table 1: All genera of the picornavirus family with their usual hosts, mode of transmission and caused diseases. 
Table modified from the book, James, S. & Allen, S. (2001). Viruses and Human Disease. US: Academic Press. 
Rhinoviruses are very similar to enteroviruses but they can be distinguished by physical 
properties, genome organization and different symptoms of the diseases they cause. As the 
name implies, enteroviruses can replicate in the alimentary tract and are resistant to low pH. 
This genus contains some important human pathogens like Poliovirus, Coxsackievirus, 
Echovirus, Human Enterovirus and many other non human enteric viruses. Rhinoviruses are 
labile at pH < 3.0 but many are already inactivated at a much higher pH; this acid lability 
plays a role in uncoating of viral RNA. 
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Properties of Rhino- and Entero-viruses 
 pH sensitivity 
Optimum growth 
temperature 
Detergent 
sensitivity 
Serotypes Transmission 
Site of primary 
infection 
Rhino 
viruses 
labile to acid 
pH 
~ 33 °C  >100 aerosol 
upper respiratory 
tract 
Entero 
viruses 
resistant to 
acid pH 
~ 37 °C resistant 72 oral-fecal gut 
 
Table 2: Properties of rhinoviruses and enteroviruses taken from http://pathmicro.med.sc.edu/virol/picorna.htm. 
Organization and expression of the genome 
 
The picornaviral genome is a single stranded RNA molecule of about 8 kb (6.5 to 9.5 kb). It contains 
one open reading frame (ORF) and is translated into a single polyprotein. This polyprotein (~2200 
amino acids) is cleaved by two virus-encoded proteinases to form different polypeptides. The 
polypeptide can be divided into three regions P1, P2 and P3. The cleavage product P1 consists of a 
polyprotein precursor for the four structural proteins of the virus, VP1–4. P1 is first cleaved in trans to 
VP0, VP1, and VP3 by 3CDpro. VP0 is later cleaved to VP2 and VP4 during virus assembly. 
The P2 and P3 region encode non-structural proteins that are important for the co-translational 
cleavage of the polyprotein (viral proteases 2A and 3C), inhibition of host cell functions (proteases 
2A, 3C and Leader protease), determination of host range (2B,2C) and replication of the viral RNA 
(2C, 3AB, Vpg and RNA polymerase 3D). 
 
Figure 2  A typical picornaviral genome with the 3 main cleavage intermediates (P1, P2, P3). Also the functions 
of the 12 major polypeptides are shown. IRES, internal ribosomal entry site; UTR, untranslated region;  Vpg, 
viral protein genome-linked. Picture taken from Ref. [2] 
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The picornaviral genome contains a small protein, VPg, covalently bound to the 5` end, which 
is the primer for initiation of RNA synthesis. VPg is normally removed from the RNA by a 
cellular enzyme, but its removal is not required for its translation. The 3` end of the RNA is 
polyadenylated. The 5` nontranslated region of a picornaviral RNA possesses an IRES 
(internal ribosome entry site) therefore the RNA is translated by a cap-independent 
mechanism. To promote the translation of the viral mRNA, rhinoviruses (and other 
picornaviruses) inhibit cap-dependent translation by cleavage of the cap binding protein 
eIF4G (eukaryotic initiation factor 4G) by the viral protease 2Apro.  
 
Virion structure 
 
Picornaviruses are spherical in shape, with a diameter of 30 nm. The particles are composed 
of a protein shell that surrounds the naked RNA. The particles are non-enveloped and are 
composed of 60 copies of the 4 structural proteins VP1, VP2, VP3 and VP4 arranged as 12 
pentamers forming an icosahedron. The capsid is responsible for specific binding to cell 
surface receptors.   
 
Figure 3: Examples of picornaviruses and their receptors used for cell entry. Picture modified from Ref. [2]. 
 
The shell is formed by VP1 to VP3, and VP4 is completely inside. VP1, VP2, and VP3 have 
no sequence homology, yet all three proteins have a similar conformation: they form an eight-
stranded, antiparallel β-barrel (also called a β-barrel jelly roll or a Swiss-roll β-barrel). This 
domain is a wedge-shaped structure made up of two antiparallel β-sheets (see. Fig.4). One ß-
sheet forms the wall of the wedge, and the second, which has a bend in the center, forms both 
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a wall and the floor. The wedge-shape facilitates the packing of structural units to form a 
dense, rigid protein shell.  
 
The main structural differences among VP1, VP2, and VP3 lie in the loops that connect the  
β-strands and the N- and C-terminal sequences that extend from the β-barrel domain. These 
amino acid sequences give each picornavirus its distinct morphology and antigenicity. The C-
termini are located on the surface of the virion, and the N-termini are on the interior. 
 
 
 
Figure 4: Left panel: Schematic of the picornavirus capsid, showing the pseudoequivalent packing arrangement 
of VP1, VP2, and VP3. Picture taken from Ref. [3]. Right panel: The typical folding of the capsid proteins (2 
antiparallel ß-sheets). http://www.med.uni-jena.de/virologie/zell/lehre/picornaviren/picornaviren.html 
The Picornaviral life cycle 
 
The life cycle of picornaviruses is shown in Figure 5. Attachment to cellular receptors (LDL-
R or ICAM-1 for rhinoviruses), is the first step. The second step is the internalization of the 
virion by receptor mediated endocytosis. During internalization uncoating takes place. The 
result of this uncoating is the release of viral RNA to the cytoplasm of the host cell. The viral 
RNA can serve directly as a template for protein synthesis. The protein synthesis is initiated 
in a cap-independent manner, via an IRES sequence located at the 5´end of the genome. The 
polyprotein is processed via protease cleavage to the different virus proteins. Some of them 
help to form the viral replication complex. During replication, a full-length complementary 
copy of the genomic RNA is produced that serves as a template for the synthesis of genomic 
RNA. This complementary RNA template is called minus-strand RNA (-). Much more 
(+)RNA than (–)RNA is produced, since (+)RNA is needed for translation and encapsidation 
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into progeny as well as for replication, whereas (–)RNA is needed only as a template for 
making (+)RNA.  
The RNA-dependent RNA polymerase 3Dpol is strictly primer dependent. In the presence of 
template, 3Dpol can uridylate VPg on a specific tyrosine residue. This nucleotidyl peptide 
then functions as a primer for the initiation of RNA synthesis. The last steps are virus 
packaging and viral egress.  
 
Figure 5: A picornaviral life cycle. The main events of infection are described in the text. (+) stranded RNA is 
shown in blue, (-)stranded RNA is shown in red. Picture taken from Reference [2]. 
 
Rhinoviruses 
 
Human rhinoviruses (HRV) are responsible for nearly 50% of all common cold infections. 
Their name (Rhinos = nose) reflects the primary site of infection. Since the discovery of 
rhinovirus in 1956 [4] [5], more than 100 serotypes have been identified.               
HRVs are the largest genus within the picornavirus family.  The human rhinoviruses are non 
enveloped viruses with a positive single strand RNA genome (7500bp). The capsid is an 
icosahedron, which is composed of 60 copies of each of the four viral proteins (VP1-VP4).  
The diameter of this T=1 pseudo T=3 capsid is 30nm. Rhinoviruses replicate predominantly 
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in the upper respiratory tract and are transmitted by direct person-to-person contact. Recently 
studies revealed that rhinoviruses are also able to replicate in lung tissue [6]. Coughing and 
sneezing, common syndromes of rhinovirus infections help spreading the virus. The 
development of an effective vaccine and antiviral prophylaxis against HRV is hampered by 
the extensive antigenic diversity.  
 
 
 
Figure 6: Icosahedral surface of HRV2 (pdb code: 1fpn) composed of the four viral proteins: VP1 colored in 
blue; VP2 colored in red; VP3 colored in green; VP4 is inside. Picture was made with UCSF Chimera [7] using 
the multi-scale model function.  
 
Symptoms of rhinovirus infection and immune­response: 
 
The symptoms of a rhinovirus infection are discharging or blocked nasal passages often 
accompanied by sneezes, a sore throat, rhinorrhea, and general malaise. The symptoms occur 
from 1 to 4 days after infection at which time extremely high titers of the rhinovirus are found 
in the nose. The symptoms experienced depend on the number of virus particles replicated. 
Infected cells produce a variety of molecules, such as histamine that result in increased nasal 
secretions. It is the production of such molecules rather than direct cellular destruction that 
accounts for the symptoms experienced by the patient. The primary infection results in the 
production of IgA in nasal secretions and IgG in the bloodstream. Since rhinoviruses do not 
enter the circulation, the mucosal IgA response is the most important. This leads to immunity 
and resolution of the disease although the levels of nasal IgA decrease rapidly. Immunity 
against a particular serotype may last 1 to 2 years. Interferon production is the primary means 
of defense, preceding the antibody response. Many infected persons (about 50%) do not show 
symptoms of a rhinovirus infection but are nevertheless capable of passing on the 
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infection. Although the lower respiratory tract is usually not affected, bronchopneumonia can 
occur in rhinovirus infections, particularly in children http://pathmicro.med.sc.edu/virol/rhino.htm. 
 
Even more important than causing common colds, rhinoviruses also trigger the great majority 
of asthma exacerbations [8]. Rhinovirus infection has also been associated with nearly half of 
all chronic obstructive pulmonary disease (COPD) exacerbations [9]. 
Classification of rhinoviruses: 
 
HRVs can be classified according to their amino acid-sequence similarity. Phylogenetic 
analysis of the capsid protein VP1 coding sequences of all 102 human rhinovirus (HRV) 
strains revealed two major genetic clusters. According to this, rhinoviruses are divided in A 
and B species. This classification correlates with the sensibility of rhinoviruses to antiviral 
compounds. Rhinoviruses A (HRVA) comprise 73 Serotypes. The average amino acid 
identity within the class of HRV A is 78% (range 68%-95%). Amino acid identity within 
HRV B is 83% (range 75%-99%) [10]. 
Based on receptor binding properties, rhinoviruses can be divided into 2 classes. The one 
class of rhinoviruses binds to ICAM-1 (intercellular adhesion molecule 1). The others bind to 
members of the LDL (low density lipoprotein)-receptor family.  
Recently, a number of sequences with high similarity to the genomes of HRVs have been 
detected in patients. These rhinovirus types have not been cultured, but their sequences 
indicated that they are a third species called HRV-C.  [11-13]. 
 
Receptors: 
 
Based on their receptor use, two groups of HRV can be distinguished. Major group viruses 
use intercellular adhesion molecule-1 (ICAM-1) as their receptor [14]. The 12 minor group 
viruses attach to low density lipoprotein (LDL) receptor, very-LDL (VLDL) receptor, and 
LDLR-related protein on the cells [15,16]. 
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ICAM­1: 
 
ICAM-1 belongs to a family of transmembrane, glycoprotein cell adhesion molecules whose 
extracellular part is composed of five immunoglobulin Ig domains. The normal function of 
human intercellular adhesion molecule-1 (ICAM-1) is to provide adhesion between 
endothelial cells and leukocytes after injury or stress. This plays a major role in the migration 
of leukocytes from the blood to sites of inflammation.  
During an inflammatory response, expression of ICAM-1 in endothelial cells is greatly 
increased. Thus, these cells become ‘‘sticky’’ to leukocytes in the circulating blood. This is 
followed by migration of leukocytes to the sites of injury or infection. 
 
 
 
1A 17 34 51 68 85 
1B 18 35 52 69 86 
2 19 36 53 70 87 
3 20 37 54 71 88 
4 21 38 55 72 89 
5 22 39 56 73 90 
6 23 40 57 74 91 
7 24 41 58 75 92 
8 25 42 59 76 93 
 9 26 43 60 77 94 
10 27 44 61 78 95 
11 28 45 62 79 96 
12 29 46 63 80 97 
13 30 47 64 81 98 
14 31 48 65 82 99 
15 32 49 66 83 100 
16 33 50 67 84 HANKS 
 
Table 3: Classification table of human rhinoviruses. HRV A species that are classified into the major group are 
colored in red, minor group viruses are colored in blue and “K-types” are colored in green. HRV B species are 
represented in bold. HRV87 in white was re-classified as enterovirus 68.  
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The normal ligands of ICAM-1 are leukocyte function-associated antigen or macrophage-1 
antigen [17] (Fig.7). 
 
 
 
 
Figure 7 left: Structure of ICAM-1with the different ligand binding sites and glycosylation sites (lollipop shaped 
structures) PFIE…Plasmodium falciparium infected erythrocytes, LFA-1… leukocyte function-associated 
antigen 1, Mac-1… macrophage-1 antigen right: A major group human rhinovirus showing the binding-site 
(canyon) of ICAM-1 (gray ring). Pictures taken from Ref. [18]. 
 
The ICAM-1 binding site of major group viruses is located at a surface depression around the 
fivefold axes, the so-called canyon, which is a  highly conserved structural feature among 
HRVs [19,20]. The canyon is composed of the north wall (built by VP1) around the fivefold 
axis and the south wall (built mainly by VP2 and VP3). While the most accessible residues 
along the canyon walls are hypervariable, the less exposed residues in the canyon floor are 
conserved and used for receptor binding; this has been thought to be a strategy allowing the 
virus to escape antibody neutralization [21]. However, it was demonstrated that antibodies can 
also access the canyon [22]. There is a hydrophobic pocket in VP1 directly underneath the 
canyon floor. This pocket is usually filled with a fatty acid (pocket factor), which stabilizes 
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the virion during its cell-to-cell transit [23]. Hydrophobic antiviral compounds (e.g. the WIN 
compounds) were found to bind to the VP1 pocket and to inhibit capsid breathing. 
 
 
 
Figure 8: Binding of a major group rhinovirus to ICAM-1. Only the 2 distal domains of ICAM-1 are presented. 
Picture taken from the book, James, S. & Allen, S. (2001). Viruses and Human Disease. US: Academic Press. 
 
LDL receptors: 
 
The members of the LDL receptor family are structurally related endocytic receptors. The 
LDL receptor family members are able to bind and internalize a plethora of ligands; as a 
consequence, they play important roles in diverse physiological processes. These receptors are 
key players in the lipoprotein metabolism, vitamin homeostasis, Ca2+ homeostasis, cell 
migration, and embryonic development [24]. A structural overview of members of the LDLR-
family that can serve as receptors for minor group viruses can be seen in Fig.9. Members of 
the low-density lipoprotein receptor family possess various numbers of ligand binding repeats 
that non-equally contribute to binding of minor group human rhinoviruses [25].  
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Figure 9:  3 members of the LDL-receptor family that are used for cell attachment of minor group viruses. 
Picture taken from Reference [26].  
 
The ligand binding domains of LDLR-family members are composed of different numbers of 
ligand binding repeats. In LDLR 7, VLDLR 8 and in LRP 31 ligand binding repeats are 
present. The regions of ligand binding repeats in LDLR, VLDLR and LRP are followed by 3 
regions that are similar to epidermal growth factor precursor (EGF repeats). These repeats are 
containing YWTD motives that form a 6 bladed ß-propeller. In LDLR and VLDLR an O-
glycosylation region is present proximal to the transmembrane domain. In the cytoplasmic 
domain a NPXY internalization motive is present. 
The attachment site on minor group viruses is located at the tip of the five-fold axis, at a star 
shaped dome, that is build by the loops of VP1. The receptor binding site of minor group 
viruses encompasses only VP1, whereas the binding site (canyon) of ICAM-1 encompasses 
VP1, VP2 and VP3 (Fig.10). 
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Figure 10: Binding sites of 2 different rhinovirus receptors. VP1 colored in blue VP2 colored in green, VP3 
colored in red. The ligand binding repeat 3 of VLDLR is colored in yellow. The 2 distal domains of ICAM-1 are 
colored in orange. 
 
Heparan sulfate: 
 
The biological functions of heparin sulfate are cell adhesion, migration proliferation and 
differentiation [27]. Heparan sulfate is ubiquitously expressed at the surface of mammalian 
cells. It is characterized by a linear chain of 50-200 disaccharide units of beta-D-glucosamine 
(GlcN) 1-4 linked to beta-D-glucuronic acid. Recently, studies on HRV54 carried out by 
Khan [28] showed that this virus type is able to attach to cells via heparin sulfate. HRV54, a 
major group virus, was able to infect human rhabdomyosarcoma (RD) cells lacking ICAM-1. 
The infection could not be blocked with a recombinant soluble concatemer of VLDLR repeat 
3 (MBP-V33333). Previously, it was shown that also variants of HRV89 are able to use 
heparin sulfate as a receptor for cell-entry. The interaction between HS and virus is basically 
an ionic interaction. A typical HS binding motive is BBXB or BBBXXB (B basic residue; X 
every residue).  Such a motive was found in the VP1 of HRV54 but it is not clear whether it is 
indeed involved in HS attachment.  
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2. Materials and Methods: 
 
 
Tissue culture medium: 
MEM (Minimal Essential Medium, Gibco) for cultivating HeLa cells. 
DMEM (Dulbecco´s Modified Eagle Medium, Gibco) for cultivating RD and RD-ICAM 
cells. 
Opti-MEM I (Gibco) for MaTra RNA transfection.  
Growth medium:  10% heat inactivated fetal calf serum (hiFCS, Gibco) ; 1% Penstrep 
(Penecillin/Streptomycin, Gibco) ; 1% L-glutamine (Gibco) 
Infection medium: 2% hiFCS ; 1% Penstrep ; 1% L-glutamine; 30 mM MgCl2 
 
Cells: 
Cells were cultivated at 37°C in 5% CO2 atmosphere.  
For infection, 34°C in 5% CO2 atmosphere. 
Culturing, Splitting and Seeding of the Cells 
Cells stored in liquid nitrogen in freezing medium (10% DMSO in FCS) were thawed and 
transferred to pre-warmed growth medium. Cells were centrifuged to remove DMSO. The cell 
were taken up in growth medium and shifted into 75 cm2 cell culture flasks (CORNING 
lifescience). When the cell had reached 100% confluence they were washed with PBS and 
splitted using trypsin-EDTA (PAA). The detached cells were resuspended in growth medium 
and a required number of cells were transferred to respective plates. An aliquot of about 1/10 
of the flask volume was used to keep the cells in culture.  
HeLa (Ohio) cells: 
Human cervical epithelial tumor cell line was obtained from European Collection of Cell 
Cultures (ECACC). 
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Rhabdomyosarcoma (RD) cells: 
Human muscle fibroblasts wild type (RD) provided by Dr. Darren S. Shaffren New Castle 
Australia 
RD-ICAM cells: 
Human muscle fibroblasts transfected with human intercellular adhesion molecule-1 (RD-
ICAM). Kindly provided by Dr. Darren S. Shaffren New Castle Australia 
Viruses: 
 
HRV2 and HRV14 viruses were originally obtained from ATCC.  
Plasmid: 
The plasmid pHRV14as3fWT was created by Tim Skern and was published in [29]. It 
contains the full cDNA genome of HRV14 embedded in the T7 cloning vector pSP72 
(Promega). The most important feature of this plasmid is its T7 promoter. That makes it 
possible to obtain infectious + stranded RNA from this vector. 
 
 
 
 
 
 
T7 promoter 
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Preparation of competent E. coli: (MgCl2 Method) 
An o/n culture of Top10 E.coli cells was inoculated into 200 ml LB medium. The cells were 
grown at 37°C till an O.D. 0.4-0.5 was reached. Then the cells were harvested in sterile 
Falcon® tubes at 4000 rpm 5 min at 4°C. The cells were resuspended in 25 ml ice-cold 0.1M 
CaCl2. After 25 min on ice the suspension was centrifuged again. (4000 rpm, 5 min).  Cells 
were resuspended in 10 ml CaCl2 and kept at 4°C over night. The next day 2ml sterile 80% 
glycerol was added. 200 µl aliquots were frozen in liquid nitrogen and stored at -80°C. 
Heat shock transformation of E.Coli: 
100 µl competent E.coli Cells were mixed with 1 µg of plasmid DNA and incubated for 20 
min on ice. Afterwards the cells were transferred into a 42°C heated water-bath for 2 min and 
for 10 min on ice. The cells were incubated with 0.8 ml LB medium at 37°C for one hour and 
plated on LB Agar (with 100 µg/ml ampicillin) and again incubated at 37°C over night. 
Plasmid preparation (MIDI): 
Cells from 50 or 100 ml o/n culture were harvested via centrifugation (5000 x g , 15 min at 
4°C) Harvested cells were resuspended in 4ml Buffer S1+RNAse (included in the 
Nucleobond–Kit) After resuspending, 4 ml of buffer S2 was added. The buffer S2 contains 
SDS and NaOH, because of these 2 ingredients the cells are lysed and the DNA is denatured. 
To neutralize the solution, 4 ml neutralization buffer (S3) was added. To separate the 
precipitated proteins and the chromosomal DNA, the solution was clarified via centrifugation 
(SS34; 15.000 rpm; 30 min; 4°C). The supernatant was applied to an equilibrated column 
(with 2.5 ml Equilibration Buffer). After one washing step (10 ml E3) the plasmid DNA was 
eluted with 5 ml elution buffer (E5). DNA in the eluted solution was precipitated with 
isopropanol and washed with 70% ethanol. The final DNA concentration was measured in the 
nano drop analyzer. 
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Restriction digest: 
The total volume of one restriction digest was 50 µl.  
Contents: 
• 1µg plasmid DNA                                                                                                                           
• 5µl Buffer (NEB buffer 1 for AvrII/KpnI; NEB buffer 2 for Acc65I) 
• 0.5µl BSA-solution (NEB) optional, only for special restriction enzymes  
• x Water (autoclaved) 
After mixing the solution was incubated for 2 hour at 37°C 
10 µl of the restricted volume were mixed with 2 µl 6x loading Dye (Fermentas) and applied 
on a 1% agarose gel (total volume 40 ml). 0.5 TBE buffer was used as running buffer. DNA 
fragments were separated via electrophoresis with 80 V / 400mA for 50 min in a mini sub cell 
electrophoresis device (BIO-RAD).  
Site directed mutagenesis (“round the horn”): 
2 primers with different sizes were used for this method of site directed mutagenesis. Primer 
HRV2 loop1 was used as forward primer. This primer does not fully base-pair with the 
template sequence (indicated with red letters in the primer-list). The shorter reverse primer 
was complement to the template sequence. The amplification results in linear mutated strands 
that had to be ligated. To exclude that the template plasmid is transformed, it had to be 
removed before transformation. The template plasmid was amplified and isolated from am 
E.coli strain with active Dam methylase. This enzyme methylates the internal cytosine 
residues of DNA (plasmids). Because of this, it was possible to selectively digest the template 
DNA with the restriction enzyme DpnI, which only cleaves when its recognition site is 
methylated. After DpnI digestion the template sequence is fully digested and therefore not 
transformed in E.coli. 
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This site directed mutagenesis method comprises 3 different steps. 
1. Phosphorylation of primers: 
Primer stock solution should be 100 µM in water.  
• 37µl water 
• 5  µl Kinase reaction buffer (NEB) 
• 1  µl 50 mM MgSO4 
• 5  µl primer 
• 1  µl 100 mM ATP 
• 1  µl T4 PNK (NEB)  
Incubation for 37°C for 60 minutes. Heat-inactivation at 65°C for 20 minutes.  
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2. PCR reaction: 
The total volume of a PCR reaction was 50 ml 
• 100ng template (HRV14-as3f WT) 
• 5 µl 5x PFU polymerase buffer (Promega®) 
• 125ng forward primer HRV2_loop1   
• 125ng reverse primer HRV14_3016rev. 
• 1 µl dNTP´s (Promega® 200µM each) 
• 1 µl Pfu Polymerase (Promega®) 
• x water 
PCR program: 
1.  95°C 2  min initial denaturation
2. 95°C 1  min denaturation 
3. 55°C 45 sec primer annealing 
4. 72°C 22 min extension 
5. 72°C 10 min final extension 
6. 4°C ∞ hold 
 
To verify whether the PCR reaction yielded the correct product, 10 µl of the PCR mix were 
applied on an agarose gel (1%). When the expected bands were observed, the remaining 
volume was digested (1h at 37°C) with 1µl of the methlyation sensitive restriction enzyme 
DpnI.  
 
3. Ligation of the PCR product: 
• 2.3 µl water 
• 2.0 µl PCR product 
• 0.5 µl 10x T4 DNA ligase buffer (NEB) 
• 0.2 µl T4 DNA ligase 
incubation over night at RT  
25 cycles 
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The entire volume of the mixture was used to transform competent E.coli (Top10) according 
the heat shock transformation protocol; cells were plated out on LB agar plates supplemented 
with 100 µg/ml ampicillin (incubation o/n at 37°C).   
 
Phenol­Chloroform extraction of DNA: 
After the restriction digest with Acc65I (to obtain a linear plasmid) the mixture was filled up 
with 450 µl autoclaved water. 500 ml Phenol/Chloroform/Isoamylalkohol solution was added 
and mixed by vortexing. After centrifugation in an Eppendorf centrifuge (full speed; 2 min) 
the aqueous layer was transferred into a new tube. 50 µl 3M NaAc (5.2 pH) and 1 ml 100% 
ethanol was added. The mixture was vortexed and incubated for 20 min at -80°C. To pellet 
the precipitated DNA the sample was centrifuged (4°C, full speed). 
DNA pellet was washed with 70% ethanol, dried and finally dissolved in RNAse free water 
(50 µl). 
In­vitro transcription: 
For the RNA transcription the Ambion® T7 MEGAscript kit was used. 
The total volume was 20µl. 
• 2 µl ATP 
• 2 µl GTP 
• 2 µl CTP 
• 2 µl UTP 
• 2 µl 10x reaction buffer 
• 1 µg linear template (Acc65I cut and phenol/chloroform extracted HRV14_as3f WT) 
• x Nuclease free water 
After mixing, the solution was incubated at 37°C for 4 hours. 
 
 
 
LiCl2 precipitation of RNA: 
The transcription reaction was stopped by adding 30 µl nuclease free water and 30 µl LiCl2 
solution. After mixing thoroughly the solution was chilled for 30 min at -20°C. To pellet the 
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RNA full speed centrifugation in an eppendorf centrifuge was carried out in the cold room 
(4°C). Subsequent a washing step with 70% ethanol the dried RNA pellet was dissolved in 
RNAse free water. The RNA concentration was measured with the nano drop analyzer. RNA 
was stored at -80°C. 
Preparation of HeLa cells for transfection and MaTra transfection: 
Hela cells were seeded in a 6-well plate (cell count 0.375*106 per well in 3ml total volume in 
growth medium). When the cells had reached 80% of confluence they were washed with PBS 
and the medium was changed to infection medium (2ml). For the transfection 198µl Opti-
MEM I medium was mixed with 1 µl RNA (conc. 3.0µg/µl) and 5 µl Matra reagent (IBA). 
For the control 200µl Opti-MEM I medium was mixed with 5µl Matra reagent (IBA). After 
vortexing, the mixture was incubated for 20 min at RT. The transfection-mixture was applied 
on the cells in the 6-well. For magnetic transfection a permanent magnetic plate was placed 
under the 6-well plate. The magnetic plate was removed after 15 min of incubation at 34°C. 
The cells were incubated for 2 days at 34°C.  
Transfection of viral RNA with Lipofectamine2000: 
80% confluent Hela cells were washed once with PBS and the medium was changed to 
infection medium (w/o antibiotics). 10 µl Lipofectamine2000 (Invitrogen) was mixed with  
200 µl of MEM medium (w/o serum and antibiotics). The RNA (3 µg) was mixed with the 
200 µl of serum free MEM. After 5 min of incubation at RT the RNA and the 
Lipofectamine2000 fraction were combined. Afterward an incubation time of 20 min the 
combined mixture (400 µl) was applied on the cells, which were incubated for 2 days at 34°C.  
Preparation of [35S]­radio labeled virus 
First, a RNA transfection (Matra) of HeLa cells, using wt HRV14 and HRV14_HI2 RNA was 
carried out. The transfected cells were incubated for 3 days at 34°C. An aliquot of the 
supernatant (300 µl) from the transfected wells was used for infection of HeLa cells that were 
grown in a 6 well plate (80% confluent). The cells in the control wells were overlaid with 
virus at 108 TCID50/well in 300µl  infection medium (HRV2 and HRV14). After 1 hour of 
shaking at 34°C, 500ml methionine/cysteine free medium was added. To remove unbound 
virus the cells were washed with PBS after 3h of incubation. Then the cells were again 
incubated for 3 hour at 34 °C in 800ml methionine/cysteine -free medium.  0.1 mCi/well of 
[35S]-methionine/cystein (Hartman Analytics Braunschweig, Germany) was added and cells 
were incubated at 34°C for 24 hours. The cells were broken by 3 freeze/thaw cycles and cell 
debris was removed by centrifuation in an Eppendorf centrifuge (14,000 rpm/10 min). The 
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supernatant was centrifuged in an ultracentrifuge at 70,000 rpm (rotor TLA 100.3, Beckman 
Instruments, USA) for 2 h at 4°C. The virus pellet was resuspended in 50 μl of virus buffer A. 
The resuspended virus was kept overnight at 4°C. The mixture was filled up with 1ml virus 
buffer A and re-centrifuged, to remove free unincorporated [35S]-methionine/cysteine. The 
virus pellet was again resuspended in 50 μl of virus buffer A. Two µl of each sample were 
mixed with 5x reducing SDS sample buffer applied on a 15% SDS-PAGE. After running the 
gel, it was dried and exposed to Kodak BioMax MR film.  
Preparation of Staphylococcus aureus cells 
500 µl of a well resuspended Staphylococcus aureus (PANSORBIN) solution was pelleted via 
centrifugation and washed 2 twice with PBS and once with RIPA buffer. After the last 
centrifugation the cells were resuspended in 400µl RIPA buffer and 100µl anti-HRV14 serum 
(rabbit). The cells were incubated at 4°C under continuous rolling over night. 
Immune precipitation of the radiolabelled samples 
Enrichment of radiolabelled virus particles was acquired by immune precipitation. 40 µl of 
the virus samples were mixed with 450 µl RIPA buffer and 25 µl of the Staphylococcus 
aureus cells with the bound anti HRV14 antibodies. After incubation for 1h under continuous 
rolling at RT the cells were centrifuged (4000 rpm, 10 min) and washed 3 times with RIPA 
buffer (500µl). The cells were resuspended in 40 µl RIPA buffer and 10µl 5x reducing SDS 
buffer were added. The samples were heated to 95°C for 5 minutes. This treatment is 
sufficient to reduce disulfides, solubilize and dissociate proteins without breaking the peptide 
bond. Finally 20 µl of the samples were applied on a 15% polyacrylamid gel and the gel was 
run. The gel was dried and exposed to Kodak BioMax MR film. 
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Site directed mutagenesis (quick change) 
For the method of quick change site directed mutagenesis two primers with the same size 
were used. The missmatches are located in the middle of the primers flanked by 12 
complementary nucleotides. No primer phosphorylation was needed, because the PCR ends in 
a circular product.  
 
 
• 1 µl plasmid template (45µg/µl) 
• 10 µl 5x Phusion® buffer 
• 1 µl dNTP 
• 1 µl primer HRV14_K; HRV2loop1 (125ng/µl) 
• 1 µl primer HRV14_Kcomp; HRV2loop1comp (125ng/µl)  
• 0,4 µl Phusion® DNA Polymerase 
• 35,6 µl water  
PCR reactions were performed in a Piko® Thermal Cycler (Finnzymes).  
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Program: 
1.  98°C 3 min  initial denaturation
2. 98°C 5 sec  denaturation 
3. 55°C 5 sec  primer annealing     
4. 72°C 3 min  extension 
5. 72°C 10 min final extension 
6. 8°C ∞  hold 
 
A subsequent DpnI digest was performed to get rid of the non mutated, methylated parental 
template DNA. 10 µl of the PCR mix were applied on an agarose gel. After having verified 
that the PCR yielded the expected bands, the mix was used to transform (heat shock 
transformation) competent E.coli. 
Reverse transcription of Virus RNA 
Exclude contamination with wt HRV14, the infective HRV14_HI clones were sequenced.  
HeLa cells were infected with HRV14_K and HRV14_HI2 viruses respectively and incubated 
for 2 days at 34°C 5% CO2. The supernatant was 3 times freezed/thawed. Cell debris was 
removed by centrifugation in an eppendorf centrifuge (14,000 rpm, 10 min). The supernatant 
was centrifuged in an ultracentrifuge (70,000 rpm,  2h). The pellet was dissolved in Tris/HCl 
buffer (pH 8.5).  
• 1 µl sample (in Tris buffer) 
• 1 µl Primer (Primer 4) 
• 1 µl dNTP´s (Promega®) 
• 1 µl RNAsin® (Promega®) 
• 1 µl DTT (Invitrogen) 
• 4 µl 5x Reverse transcription buffer 
• 1 µl SuperScript® III reverse transcriptase (Invitrogen) 
• 9 µl Nuclease free water (Promega®) 
 
25 cycles 
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Program: 
1. 55°C 10min 
RNA release from 
eventually present virus 
2. 4°C 3min cooling step 
3. 45°C 60min reverse transcription 
4. 70°C 15min inactivate enzyme 
5. 4°C ∞ hold 
Amplification of the cDNA 
 
To obtain double stranded DNA in sufficiently high amount for sequencing, a normal PCR 
reaction was performed.  
 
• 1µl reverse transcribed DNA 
• 1µl dNTP´s (Promega®) 
• 1µl forward primer 10pM (HRV14_2420) 
• 1µl reverse primer 10pM (Primer4) 
• 5µl 10x Pfu® buffer (Promega®) 
• 0.4µl Pfu® DNA Polymerase (Promega®) 
• 40.6µl water 
 
Program: 
1. 95°C 1 min  initial denaturation 
2. 95°C 30 sec  denaturation 
 3. 50°C  30 sec  primer annealing 
4. 72°C 90 sec  extension         
5. 72°C 10min  final extension 
6.    4°C ∞ hold 
25 cycles 
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After the PCR reaction 1 µl of the PCR mix was applied on an agarose gel (1%). An aliquot 
of the PCR mix together with the HRV14_2420 primer (10pM) were sent to the IMP 
sequencing service. The file containing the sequencing results was opened with                  
CLC Sequence Viewer and aligned with the VP1 sequence of HRV14. 
Virus infection assay 
RD and RD-ICAM cells were grown in a 48 well plate to ~80% confluence. After washing 
with PBS, the cells were covered with 200 µl DMEM infection medium. Supernatant 
containing the chimeric HRV14 was added to the cells in 1:2 dilutions steps. The cells were 
incubated 3 days at 34°C 5% CO2. The CPE was monitored by staining with crystal violet 
(1% in water). 
Primer list: 
 
>HRV2_loop1   
CATTCAGAATAGTAACAGAGAAACACATTCATAAAACTCTTGTC 
>HRV2_loop1 comp 
GACAAGAGTTTTATGAATGTGTTTCTCTGTTACTATTCTGAATG 
44nt GC=31.8%  TM=72.3°C  * 
>HRV14_3016rev. 
CCATACTACCCATATGGTTTAGAA 
24nt GC=37.5% TM=60.0°C * 
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>HRV14_2420 
GTCCCCATACTAACTGCAAAC     
21nt GC=47.6%  TM=60.4°C * 
>HRV14_K       
CAGAATAGTAAATGAAAAAGATGAACATAAAACTC  
>HRV14_K_comp  
GAGTTTTATGTTCATCTTTTTCATTTACTATTCTG 
35nt GC=25.7% TM=65.4°C * 
>Primer 4 
GGCTTTTCACAAATTATGGGGTAATAC 
27nt GC=37.0% TM=65.9°C * 
 
*calculated with the finnzymes TM calculator https://www.finnzymes.fi/tm_determination.html   using the 
modified Breslauer´s thermodynamics, dH° and dS° parameters [30]. Nucleotides that do not base pair correctly 
with the template sequence are in red.  
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Objectives: 
 
Minor group human rhinoviruses use LDLR family members to attach to host cells. After the 
X-ray structure of HRV2 bound to a fragment of its cellular receptor was determined, new 
insights about the specific receptor recognition of a minor group virus were obtained by 
analyzing the structures. The receptor-recognizing part of the virion is VP1, more specifically 
the BC and the HI loop. The analysis of the structural data revealed that a strictly conserved 
lysine in the HI loop is the key player in the interaction of all 12 minor group viruses with 
these receptors. In the case of HRV2, lysine 224 in VP1 interacts with residues of the acidic 
cluster in the V3 repeat of VLDLR. The other important contribution of this lysine is a 
hydrophobic interaction with a tryptophan residue in V3. The lysine is conserved in all minor 
group viruses and obviously responsible for their receptor specificity. In 2006 all VP1 
sequences of the known rhinovirus types were published; ten HRVs were found to also 
possess a lysine in the HI-loop at the equivalent position, however, these belong to the group 
of ICAM-1 binding rhinoviruses. Further investigations with respect to their LDLR binding 
abilities revealed that this group of major group viruses does not use LDL receptor family 
members for cell entry and hence are typical major group viruses. They were called "K-
types". The VP1-VLDLR interaction cannot be uniquely determined by a single lysine residue 
in the HI loop of VP1. It is assumed that the interaction is born out of a combination of 
different interactions of amino acids, structural features of the surface loops, and the 
distribution of electrostatic charges on the surface of the interaction partners.  
The aim of the presented work was to shed more light onto the basis of receptor recognition of 
minor group viruses. In particular, it should be attempted to change receptor specificity by a 
mutational approach and to classify minor group and K-type viruses by using bioinformatic 
methods.  
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3. Predictive bioinformatic identification of minor receptor group 
human rhinoviruses. 
 
3.1 Introduction: 
The goal of this project was to assess whether a simple and largely automated bioinformatic 
approach is able to classifying human rhinoviruses into the two receptor groups (major and 
minor group). Furthermore, we asked whether this approach can detect differences in binding 
of minor group and K-type viruses. In the following work we tried to obtain theoretical 
energy values that represent the binding affinity of rhinovirus protein VP1 to module 3 of the 
very-low density lipoprotein receptor (VLDLR).  
3.2 Details of the rhinovirus – VLDL­receptor interaction:  
Cryo-electron microscopy and X-ray structural analysis of complexes between HRV2 and 
recombinant receptor fragments [31,32] revealed that only VP1 interacts with the host 
receptor (VLDLR). Contacts between the viral protein and the receptor are located in loops 
that build a star-shaped dome at the five-fold axis close to the icosahedral vertex [33] . In 
picture 11 (left) the 3 VP1 surface loops of HRV2 are presented in ribbon representation. The 
picture on the right represents 2 symmetry related copies of VP1 interacting with V3 of 
VLDLR. The important amino acid residues of VP1 and V3 are labelled.  
Because only VP1 is interacting with the VLDLR repeat 3 we only consider this protein for 
the following calculations. To mimic the structural interface of the virus–receptor binding, we 
use 2 copies of VP1 that are arranged in the same way as in the virion. 
 
                        
Figure 11: left 3D structure of VP1 with the receptor interacting loops. right 2 Two copies of HRV2 VP1 
interacting with the module 3 of the very-low density lipoprotein receptor. 
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The key player in the interaction is a lysine at the position 224 in VP1 of HRV2. This lysine is 
strictly conserved within minor group viruses and it was believed that it was the only 
determinant for the interaction of minor group viruses and the LDL receptors. However, 
alignment of the VP1 sequences of all known HRV types revealed that some major group 
rhinoviruses also possess a lysine at the equivalent location. The types possessing a lysine 
residue in the HI loop are summarized in the alignment in figure 12. This lysine residue is 
found in 10 different HRV-types that were classified as non LDLR HRV´s. These viruses 
cannot infect cell via LDLR and/or LRP; they are neutralized by soluble ICAM-1 [34], also 
the infection of HeLa cells can be blocked with a monoclonal antibody against ICAM-1 [35].  
It was shown experimentally that some of these viruses are weak binders of MBP-V33333, 
whereas binding to LDLR was never observed. Because of the absence of binding, although 
possessing a lysine in the HI-loop, these rhinoviruses represent a quite interesting group 
within the rhinovirus genus. These viruses were consequently called “K-types”. Now the 
question arose, which additional interactions are responsible for binding of minor group 
viruses to VLDLR. However, there is no obvious conservation of any of the residues at the 
virus / receptor interface. Even when taking into account spatial vicinity within the three-
dimensional structure, no obviously conserved amino acid pattern is apparent and only 
recently the basis of receptor specificity emerged as a combination of charge complementarity 
and hydrophobic interactions [36]. Hoping to obtain new insights about the specificity of 
binding of minor group and K-type viruses we started this project. 
 
 
Figure 12:  Alignment of minor group and K-Type viruses. The strictly conserved K in the HI loop is coloured 
in red. Virus types belonging to the minor group are written in bold.  
HI ‐loop
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3.3 Workflow of the method: 
 
 
 
3.4 Modelling and evaluation of VP1 structures 
The basis of our energy calculations are 3D structures of VP1. Unfortunately only a few X-
ray structures of rhinoviral capsid proteins are determined. By now only X-ray structures of 
HRV1A, HRV2, HRV3, HRV14 and HRV16 are available. Since the number of possible 
folds in nature appears to be limited and the 3D structure of proteins is better conserved than 
their sequence [37], it should be possible to obtain 3D structures of VP1  for most of the 101 
rhinovirus types. Moreover the characteristic folding of VP1, called beta-barrel jelly roll, 
which is a common folding of spherical viruses, is conserved in all rhinovirus types.  
A homology modelling comprises usually four steps:  (I) identification of structural templates 
(II) alignment of target sequence and template structures (III) model building and (IV) model 
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quality evaluation. The first three steps are carried out automatically by the Swiss-model 
workspace, which is a benchmark in homology modelling.  
The VP1 sequences of the 101 HRVs [38] were downloaded from the UniProt 
knowledgebase. HRV87 has been identified to be an acid-sensitive enterovirus, EV68 [39], 
and was therefore not included. Note that based on antigenic cross reactivity and sequence 
similarity HRV8 and HRV95 were combined into one single type [38]. Since there are 
differences within the area equivalent to the receptor footprint they were considered as two 
separate types. The sequences were aligned with ClustalW and truncated by removal of 70 
residues from the N-terminus and as many from the C-terminus as to leave 180 residues. The 
removal of the residues that are not in immediate proximity to the interface of VP1 and 
receptor should reduce the computer calculation time. The resulting sequences were submitted 
to SwissModel [40] in ‘first approach mode’ with default parameters by using a PERL script 
for automation. Except from HRV7 and HRV69 models were obtained for all HRVs. For the 
latter two, no structure was obtained by Swiss-model using the first approach mode. The 2 
types were excluded from the analysis, being aware that the optimized mode of swiss-model 
[41], can obtain a structure, when the 3D structure of HRV3 was used as a template. To avoid 
too much bias we decided to simply exclude these two types from the subsequent analysis. 
Finally, 3D models of 99 VP1 proteins including the BC, DE, and HI loops making up the 
receptor-binding epitope were obtained.  
3.5 Evaluating the result of the homology modelled VP1 structures: 
Assessing the quality of the obtained 3D VP1 models, we used the following approach. The 5 
VP1 sequences of rhinoviruses, whose experimental structures are available, were modelled 
using the project mode of the swiss-model webpage, selecting the second best template for 
modelling. In this way we excluded that swiss-model considers the experimentally determined 
3D structures from modelling. The table 4 shows the obtained RSMD values for the modelled 
VP1 structures. All models were within less than 0.65 Å RSMD for the backbone and less 
than 0.74 Å with the side chains included, from the experimental structure indicating good 
quality of the models. 
To retrace which templates were selected by 'automatic mode' of SwissModel to model the 
different structures of the HRV types we summarized the usage of templates in Fig. 5. In 
accordance with the phylogenetic relationships [42] the program automatically selected the 
PDB coordinates of B-type viruses HRV3 and HRV14 as templates for modelling of VP1 of 
the other B-types. For modelling the A-type viruses, coordinates of HRV1A, HRV2 or 
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HRV16 were automatically chosen as templates for modelling. With regard of the receptor 
groups there was no particular preference of the minor group types for any of the type-A 
templates whereas for the K-types only HRV1A was used. As expected, for those types whose 
experimental structure was available (HRV1A, 2, 3, 14, and 16) their corresponding data were 
selected for model building. It turned out that some types were more often used as templates 
than others. Surprisingly HRV1A seems to be the most universal template as it was used for 
more than 50 % of all HRVs.  
 
Type used template RMSD Cα RMSD backbone + side 
chains 
HRV1A 1aym [HRV16] 0,64 Å 0,73 Å 
HRV2 1aym [HRV16] 0,57 Å 0,60 Å 
HRV3 1k5m [HRV14] 0,50 Å 0,53 Å 
HRV14 1rhi    [HRV3] 0,50 Å 0,55 Å 
HRV16 1r1a  [HRV1A] 0,61 Å 0,70 Å 
 
Table 4: Quality of the 3-D modeling. Models of HRVs whose 3D structure is known were automatically built 
by excluding themselves as template. Sequences were submitted to "template search" in SwissModel and the 
"second best template" (parenthesis) was chosen for modeling with "optimized project mode". RMSD (root 
mean square deviation) was derived from superposition of models and experimental structures by using the 
"iterative magic fit" function in SPDBV4.0.  
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HRV1A HRV 2 HRV 3 HRV14 HRV16 
1r1a 1fpn 1rhi 1k5m 1aym 
1A 95 39 65 2 70 5 25 
1B 98 41 66 23 91 6 62 
29 11 43 68 30 3 14 10 
31 12 46 71 49 4 27 16 
44 13 50 73 9 17 37 21 
47 15 51 74 32 26 48 * 45 
8 19 53 75 67 35 52 77 
18 20 55 76 
 
42 72 * 81 
24 22 57 78 79 84 90 
40 28 59 80 83 86 96 
54 33 60 82 92 93 100 
56 34 61 88 99 97 HANKS 
58 36 63 89     
85 38 64 94   *1rud  
 
Table 5: Templates automatically selected by SwissModel for modeling VP1 of all HRVs. Blue, minor group; 
red, genus A major group; green, K-types; orange, genus B major group; grey, HRV70 and HRV91 whose 
modeling led to strong crashes with V3. Striped, HRVs whose 3D X-ray structures are available. Note that in 
case of HRV48 and HRV72 the structure of HRV14 containing the antiviral capsid-binding hydrophobic 
antiviral compound WIN 52084 [43] was automatically selected for modeling (accession number 1rud) .  
 
 
3.6 Modelling VP1­VP1*­V3 
Since the footprint of V3 extends over two symmetry-related copies of VP1, VP1-VP1* 
'dimer' were assembled by superposition onto the experimental structure of VP1-VP1* of 
HRV2 by ‘magic fit’ using an SDBV4.0 script [44]. The correct coordinates for the 
dimerization were taken from the oligomer generator at the viper-db site [45]. The VP1-
dimers were minimized with the Gromos96 [46] force field energy minimization method (100 
cycles, steepest decent, which is part of SPDBV). The assembly of the 2 copies of VP1, as 
well as the energy minimization was carried out with SPDBV 3.7 with a script. The final 
structures of the respective VP1-VP1*-V3 'trimers' were obtained by superposition and 
combination with the coordinates of V3 taken from the HRV2-V23 X-ray structure [33]. The 
Ca2+ ion that is complexed by the receptor is not considered because no topology was 
available in SPDBV. Coordinates of these complexes were again energy minimized as above. 
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During the assembly of 2 VP1 models with V3, chain identifiers were allocated to the 
different peptide chains. The two VP1 chains received the chain IDs ´A´ and ´B´; the receptor 
received the chain ID ´R´. The chain IDs are important for the submission to energy 
calculation servers. These ‘trimers’ (VP1-VP1*-V3) were again minimized as above. 
Modelling of the HRV70 and HRV91 receptor complexes did not result in reasonable 
structures as their BC loops clashed with V3; this problem was not resolved by energy 
minimization (See structures in Fig. 13). As HRV70 and HRV91 are typical major group 
HRVs and not K-types we made no further effort to improve the models and excluded them 
from further analysis. 
 
 
 
Figure 13: Steric clashes of the BC-loops of HRV91 (left) and HRV70 (right) and the receptor. VP1and VP1´ 
colored in blue. VLDLR repeat 3 colored in yellow. 
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3.7 Energy calculations 
Models of VP1-VP1*-V3 were submitted to the Dcomplex web server [47] 
(http://sparks.informatics. iupui.edu/song/complex.html); datasets were entered and results retrieved 
automatically by using a PERL script. One set of data containing VP1-VP1*-V3 coordinates 
that had been energy minimized in SPDBV3.7 (as described above), the other contains files 
that were energy minimized with Jackal minst  (30 cycles).  
Models were also submitted to the FastContact2.0 web server 
(http://structure.pitt.edu/servers/fastcontact/). Tree different data sets were submitted to the 
fastcontact webserver. Similar to the 2 different datasets that were submitted to Dcomplex, 
these datasets only differed in the way their energy was minimized. One set was again prior 
energy minimized by SPDBV 3.7 the other by Jackal. (100 cyles for SPDBV; 30 cycles for 
Jackal). The used number of cycles in the jackal and SPDBV minimization was chosen after 
different test runs, where the same protein was minimized with different number of cycles, 
followed by comparison of the energy values. Higher values than those we have used (30 
cycles in Jackal; 100 cycles in SPDBV), only marginally lowered the energy of the protein, 
therefore we did not use a higher number of cycles. The third set of data contained the 
coordinates without any prior energy minimization. With this set of data we wanted to show 
whether prior minimization is required to obtain good a classification of the respective HRVs. 
Note that the online version of Fastcontact 2.0 performs an energy minimization using 
CHARMm parameters.  
Before the VP1-VP1*-V3 structures can be submitted to the Fastcontact 2.0 web server, they 
have to be dissected into 2 files; one containing the receptor (V3), the other one containing the 
VP1 ´dimer´. This separation of the files was carried out by using a script. The submission to 
Fastcontact 2.0 was done manually. A local copy of the Fastcontact program, kindly 
provided by the author [48,49], that is not able to minimize the entered structures with 
CHARMm, was tested as well.  
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3.8 Result of the energy calculations 
Having verified that our approach resulted in 3D models very well matching the known X-ray 
structures, we assumed that the other models were plausible and close to reality. Thus, we 
next asked whether the binding energies calculated for the complexes between the receptor 
module and the respective virus correlate with the classification established from binding 
experiments [35,50]. All models were either energy minimized with the SPDBV-inbuilt 
GROMOS96 or with Jackal [51] (http://trantor.bioc.columbia.edu/programs/jackal) and subjected to 
energy calculation via Fastcontact 2.0 and Dcomplex. As the Fastcontact online server again 
energy minimize the structures using the program CHARMm, in order to prevent automatic 
minimization with CHARMm, therefore we tested a that does not include the minimization 
step, a local copy of Fastcontact 1.0 was tested as well. In this case the coordinates were only 
minimized with the SPDBV inbuilt Gromos96. The results of the calculations are summarized 
in Figures 14 and 15. Overall, major and minor group viruses were quite well separated by 
Fastcontact regardless of the minimization method used (Fig. 14 A-C). When taking the 
correct classification of minor group HRVs as a criterion, Fastcontact 2.0 run on the 
webserver clearly gave the best results (Fig. 14 A). Nevertheless, drawing a threshold line 
either included 2 K-type viruses (HRV18, 98) in the minor group or led to misclassification of 
two minor group viruses (HRV2 and HRV47) that were then grouped together with the K-
types. The separation of minor group HRVs and K-types was heavily compromised when 
minimization by SPDBV was omitted and carried out by the web based Fastcontact alone 
(Fig. 14 B). Minimization with Jackal did not improve this situation (Fig. 14 C) and 
Dcomplex was even unable to reliably separate the minor and the major group, neither after 
minimization with SPDBV (Fig. 15 D) nor with Jackal (Fig. 15 E). Results obtained from the 
local copy of Fastcontact 1.0 where not reasonable suggesting that the additional CHARMm 
minimization step, that is not included in the local executable program of fastcontact is 
important to obtain reasonable results. (data not shown). It is also possible that this earlier 
version of fastcontact has inferior performance.  
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Figure 14. Net interaction free energy (sum of the desolvation and the electrostatic energy) of the binding of V3 
to 97 HRV types, listed on the horizontal axis, calculated with A) FastContact webserver after energy 
minimization with SPDBV3.7, B) FastContact webserver without prior energy minimization with SPDBV3.7,  C) 
FastContact webserver after energy minimization with Jackal. The viruses are positioned according to their 
number. Minor group viruses are colored in blue, major group viruses in red and K-type viruses in green. 
The best method of energy calculation (Fascontact 2.0 online server; Fig. 14A) could separate 
all non-K-type major group viruses from the minor group viruses. However, the K-types 
HRV18 and 98 and the minor group viruses HRV2, HRV47, and HRV49 (between the two 
lines) exhibit almost the same predicted binding affinities.  
49 
 
 
Figure 15: Results of the free energy calculation with Dcomplex either energy minimized with SpdbV3.7 21D or 
with Jackal seen in 21E. In both cases it was not possible to distinguish between major and minor group viruses.  
Major (red), minor (blue), and K-type viruses (green) are positioned according to their number. 
3.9 Correction of calculated affinities: 
Fastcontact not only calculates the electrostatic (4r), desolvation free, and the van der Waals 
(CHARMm19) energy but also outputs the twenty residue pairs with lowest (attraction) and 
highest energy values (repulsion), respectively. A closer inspection of the 10 best and 10 
worst energy contributions of receptor-VP1 interaction, drew our attention to the first cysteine 
in the receptor module that forms a disulphide bridge with the 3rd cysteine [52] because it 
unexpectedly was in the list of interacting residues. Fastcontact also sends back the 
coordinates corresponding to the energy-minimized structure used for calculation of the 
binding energies; this enabled us to visually inspect these coordinates. It revealed that all 
disulphide bridges had been opened thereby providing -SH groups potentially interacting with 
residues of the virus (see Fig. 16).  
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Figure 16:  A ribbon presentation of the VLDL receptor module 3 before (left) and after fastcontact submission 
(right). 
Presumably the free –SH groups of the cysteins were able to establish hydrogen bonds to 
suitable oxygen atoms nearby which were taken into account in the energy calculations. For 
the reasons mentioned above, these cystein interactions are not meaningful and can be 
definitely excluded. Therefore, we subtracted the energy values contributed by the receptor 
cysteins from the total sum of the interaction energies. This strongly improved the final result. 
The representation of the corrected binding affinities can be seen in Figure 17. It was now 
possible to draw a line that separates all minor group viruses from the K-type viruses. The 
highest binding affinity was calculated for HRV8 that is known to exhibit weak binding to the 
pentameric fusion protein MBP-V33333. 
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Figure 17:  Energy table of all minor group and K-Type viruses and representation of the final results.  Minor 
(blue) and K-Type (green) viruses are perfectly separated (separation line). Note that the not meaningful cystein 
interactions are subtracted from the predicted energy values.   
3.10 Evaluation of the results: 
Minor group viruses and K-types were successfully separated. However the differences 
between HRV47 and HRV8 were marginal. Neutralization experiments with VLDL-receptor 
derivatives did show a strong neutralization in the case of HRV47, whereas infection of 
HRV8 could not be blocked [33,50]. Neutralization assays are not the best way to 
demonstrate VLDLR-binding of minor group viruses, because major group viruses, like 
HRV8 use ICAM-1 for cell entry. A better assay for demonstrating binding of K-type viruses 
is a virus overlay blot. Since interaction of single receptor modules is very weak (even with 
minor group HRVs) and only increases upon concatenation [53,54], maltose binding protein 
fused to five consecutive copies of V3 (MBP-V33333) was used for binding experiments 
[55].  The data presented in Fig. 18 was obtained by Khan, A.G. It shows that the in-silico 
binding results match the experimental observations. This figure shows the result of a ligand 
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binding blot using HRV2, HRV8, HRV85 and HRV14. As expected from my calculations, 
HRV8 indeed bound this receptor derivative weakly when compared to HRV2 that exhibited 
very strong binding. The K-type virus with the lowest predicted affinity, HRV85 showed no 
detectable affinity for the VLDLR-concatemer MBP-V33333. No binding was seen in case of 
HRV14. This further demonstrates that an approximate prediction of the relative affinities 
from 3D models is possible although the absolute values are certainly not correct.  
 
Figure 18: Ligand blot to detect binding of radiolabeled HRVs to MBP-V33333. Recombinant receptor was run 
on an SDS 10% polyacrylamide gel under non-reducing conditions and transferred to a PDV-membrane. Strips 
were incubated with 20,000 cpm each of 35S-methionine labeled virus as indicated and exposed to X-ray film. 
Note binding of HRV2, weak binding of HRV8 and absence of binding of HRV85 and HRV14.   
 
3.11 Different contribution of amino acid residues to the binding energy: 
According to the affinities minor and K-types are well separated. The question arose whether 
minor group and K-type viruses show different binding patterns. The 10 best and the 10 worst 
interactions, taken from the text-file that is part of the Fastcontact output, are represented in a 
heat map. The energy values of the interactions of receptor (V3) and VP1-VP1* dimer are 
indicated in the boxes in kcal/mol. Negative energy values are colored in different shades of 
red. Repulsive interactions with positive energy values are presented in different shades of 
blue. 
As expected, even in the K-type viruses, that show very weakly binding to the receptor, the 
lysine in the HI loop clearly emerged as the central player by interacting with glutamic and 
aspartic acid residues in the acidic cluster around the central Ca2+ ion of the receptor module. 
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In addition, various other residues were seen to differently contribute. The low binding 
affinity of HRV85, that showed undetectable binding affinity in the ligand blots, can be 
explained with a high repulsive interaction of D89 in the first copy of VP1 and E25 in the 
receptor.  
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Figure 19: Heatmap representation of the 10 best (attraction) and 10 worst (repulsion) interactions of the VP1-
VP1*-V3 complex. The interacting residues of the receptor are presented horizontally. Vertically presented are 
the interactions with the 2 copies of VP1. Residues of the first copy are in bold; residues of the second copy are 
in italics. Energy values are given in kcal/mol.  
 
 
To check whether there are significant differences in the interaction of minor group and K-
type viruses with respect to receptor interactions, bar diagrams depicting the contribution of 
each of the receptor residues were drawn for all minor and K-type viruses. (Fig. 20) The sum 
of the interaction energies of the single receptor residues were represented in vertical bars.  
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Figure 20: Bar diagrams depicting the interactions [kcal/mol] of the receptor residues (V3). Repulsive energies 
are colored in different shades of blue. Attractant energies are colored in different shades of red. Bar diagrams of 
K-type viruses have a green background color. Note that the presented energy values are a sum of all interactions 
at this receptor residue. 
The summary table in Figure 21 shows the mean values of each receptor residue. Only energy 
contributions of a distinct receptor residue that are observed in more than 2 viruses of the 
same receptor group were considered in the analysis in Fig.21. K-type receptor interactions 
are colored green; minor group receptor interactions are colored blue. The error bars indicate 
the standard error of the mean. To assess whether the observed differences between minor and 
K-type viruses are statistically relevant, a statistical t-test (95%) was carried out. Significant 
differences were observed for 6 receptor residues. These receptor residues are marked with an 
asterix.  Summarizing the detected differences obtained by the heatmap and the receptor bar 
diagrams, interactions with acidic receptor residues are stronger for the minor group HRVs. 
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repeat 3 for LDLR repeat 5 of human and mouse, the structures were superimposed in SPDBV 
3.7 using the iterative magic fit function. Once models of VP1-VP1* L5 (human/mouse) were 
produced their structure was energy minimized in SPDBV 3.7(100cycles). As the calculations 
with V3 of human VLDLR clearly indicated that Fastcontact gives the best result, the trimeric 
complexes were only submitted to this webserver.  
 
Figure 22: Alignment of human VLDL receptor repeat 3, L5 of human LDL receptor, and the murine homolog 
of L5. The percentage conservation is indicated as bar diagram below the alignment.  
The L5 modules of human and mouse share 80% sequence identity. Whereas L5 (human and 
mouse) and V3 only share about 50% of the amino acid residues. However, the acidic clusters 
at the C-terminal end of receptor repeats are well conserved. Also the important tryptophan 
residue is fully conserved. The 3D structures of all 3 receptors are very similar. The similar 
folding of the 3 receptor fragments (V3, L5 human and L5 mouse) can be seen in Fig.23. 
  
Figure 23:  Structural comparison of V3 (red), human L5 (blue) and mouse L5 (yellow). No experimental 
structure of mouse L5 is known, thus we used a homology model. Most important residues for the interaction 
with virus VP1 are shown in stick representation.  Note that human L5 does not possess a glutamic acid at 
position 30, which is an interaction partner of the strictly conserved lysine in the HI-loop. The position in the 
alignment and in the 3D structure is indicated with a black star. 
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4.1 Result of the Fastcontact calculations: 
The replacement of the VLDLR repeat 3 through repeat 5 of LDLR or the mouse homolog 
respectively, revealed different binding affinities for some minor group viruses. The overall 
result using the mouse homolog of the LDLR ligand-repeat 5 instead of V3 (VLDLR) showed 
a similar performance regarding the separation of major and minor group viruses. (see Fig 24 
M) It was possible to draw a separation line between major and minor group viruses. The only 
minor group virus type that showed a low binding affinity was HRV1B. In the case of the 
human L5(Fig.24 H), no clear separation of minor and major group viruses was obtained. The 
lowest affinities within the minor group viruses were calculated for HRV1A, HRV1B and 
HRV47.  
 
FIGURE 24: Calculated affinities of rhinoviruses for LDLR repeat 5 of mouse (M) and human (H). Note that 
the affinities of the minor group viruses (blue diamonds) and K-type (green diamonds) viruses were corrected 
with respect to the meaningless cysteine-interactions.  
The low binding affinitiy of HRV1A to human L5 was proven by experimental approaches, 
see publication of Herdy [56]. According to her observations HRV1A strongly prefers the 
murine L5. This preference can be seen in Figure 28 M, where HRV1As calculated binding 
affinity was below the separation line. HRV1B shows low affinities for human and mouse 
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receptor repeat 5. These in-silico observations contradict the knowledge about the binding 
abilities of HRV1B. As a typical minor group virus HRV1B should be able to bind to the 
LDL receptor. Its ability to bind and infect mouse respiratory epithelial cells was shown in the 
work of Tuthill [58]. HRV47 is also predicted to have low affinity toward human LDLR L5 
but this has not been shown experimentally. An explanation why HRV1B according to the 
energy calculations neither binds, the human L5 nor the mouse L5 with high affinities can be 
correlated with a bad 3D model of its VP1 loops. The fact that the protein sequence of 
HRV1B does not differ much from HRV1A, a minor group rhinovirus with already 
determined VP1 structure, weakens this argument. Furthermore, it is more likely that the 
quality of the 3D VP1 structure of HRV47 is rather low. Indication for this can also be seen in 
the results of the first calculations with V3, where HRV47 was predicted to have the lowest 
affinity to V3 of the VLDLR. Maybe also HRV47 has the same preference as HRV1A to the 
mouse homolog and does not bind the human LDLR. A possible reason why the human L5 
does not support binding of rhinoviruses in excess, is that at position 30 the amino acid 
glycine is present. The other receptors possess in this position a glutamic acid (D25 in V3, 
D30 in mouse L5). This acidic residue is strongly involved in the virus receptor interaction 
(see Fig.19 and 21; especially pay attention to the energy contribution of E25). The favorable 
interaction partner of the glutamic acid is the conserved lysine in the HI-loop. (see heatmap in 
Fig.19) In contrast the glycine in human L5 is not able to interact with residues of the virus.  
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5.  Bioinformatic analysis of the field isolated rhinoviruses: 
 
5.1 Introduction: 
Having shown the utility of this bioinformatic approach for the separation of minor group and 
K-type viruses we wanted to analyze 2 non classified rhinovirus field isolates. This was a 
great opportunity to assess the reliability of this bioinformatics approach. 
 
These analyzed field isolates that were collected during a study about surveillance of 
enteroviruses in environmental specimens [59]. The study comprising data of 2001 to 2007, 
unclassified HRV field isolates were detected by using methods with optimized conditions for 
detecting enteroviruses, like poliovirus. Two of these unclassified HRV field samples are 
potentially interesting objects for studying the minor group receptor interactions, because a 
phylogenetic analysis revealed a close relationship to minor group viruses HRV1A and 
HRV1B. The fact which made these viruses even more interesting for our virus receptor 
interaction studies was that these sequences do not possess the strictly conserved lysine in the 
HI-loop that is a hallmark for minor group and K-type viruses. In the field isolates the lysine 
was replaced by an arginine. The question arose whether viruses possessing arginine instead 
of lysine can bind to LDLR family members. Site directed mutagenesis experiments, where 
the strictly conserved lysine was replaced by residues present at the same position in major 
group viruses, resulted in a lack of infectivity [60]. However, lysine has not been replaced by 
arginine so far. Arginine seems to be a proper substitute for lysine, as the basic character is 
maintained. Moreover, a similar interaction of an arginine residue in LDLA with the 
hemoglobin subunit b of lumbricus erythrocruorin was observed [61]. Erythrocruorin is an 
extracellular respiratory protein in the earthworm lumbricus terrestris. This protein is 
assembled from 180 polypeptide chains into an overall hexagonal bilayer shape. The 
interesting part of erythrocruorin for us is the cysteine-rich LDL-A module that is 
homologous to the low-density lipoprotein (LDL) receptor. LDL-A modules interact with a 
hemoglobin b subunit in a similar way minor group rhinoviruses do. In this case the most 
involved amino acid is an arginine (Fig.25).  
 
The sequences and virus samples we obtained from the author of the study[59]. 
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Figure 25: Interaction of the LDL-A part of lumbricus erythrocruorin (blue) with a hemoglobin b subunit 
(brown). The calcium ion is colored in green and the 3 disulfide bonds are colored orange. The interacting 
arginine residue of the hemoglobin subunit b is colored in yellow. Illustration taken from the publication of 
Royer [61]. 
 
 
 
 
5.2 Bioinformatic affinity calculations: 
The 2 VP1 sequences were treated in exactly the same way as the already classified one. For 
both field isolates HRV1A was selected by swissmodel as a template for modeling. This was 
not unexpected, because the 2 isolates share more than 92% protein-sequence identity with 
HRV1A. Thus, we can be sure that the predicted 3D structure is close to reality. For the 
energy calculation the online tool Fastcontat 2.0 was used as before.  
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Figure 33: Heatmap representation of the 10 most repulsive and most attractive interactions. Receptor residues 
are written horizontally; VP1 residues vertically. VP1 residues from the first copy are in bold letters. Residues 
from the symmetry related copy are in italic. The values in the boxes represent the calculated energy (in 
kcal/mol) contribution of a distinct interaction of 2 amino acid residues.  
 
Although the 2 field isolates do not differ much from HRV1A with respect to sequence, their 
calculated affinities and the binding pattern do. Whereas, only marginal differences between 
the 2 field isolates were found. In both field isolates, the highest attractant contribution of a 
single residue is found at the position 228 (arginine).  The calculated interaction of this 
arginine 228 residue was surprisingly higher than the interaction of lysine 228 in HRV1A. 
The differences in the affinity cannot be explained by analyzing the 10 best and worst 
interactions using a heat map. For this reason another representation for displaying the 
interaction was used.  
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5.4 Detection of binding abilities of the field isolated viruses: 
 
With this experiment we wanted to determine the binding abilities of the in-silico analyzed 
field isolated rhinoviruses. To assess the binding abilities a ligand binding blot was carried 
out. 
 
Figure 35: Ligand blot to detect binding of radiolabeled HRVs to MBP-V33333. Recombinant receptor was run 
on an SDS 10% polyacrylamide gel under non-reducing conditions and transferred to a PDV-membrane. Strips 
were incubated with 20,000 cpm each of 35S-methionine labeled virus as indicated and exposed to X-ray film. 
HRV2, HRV18 and HRV8 were used as controls. HRV2 and HRV8 strongly bind to the receptor concatemer. 
HRV18 did not show any binding to MBP-V33333. The 2 examined field isolated rhinovirus types definitely 
bind to MBP-V33333, but not in such a great manner as the minor group virus HRV2 and the K-Type HRV8. 
This experiment was carried out by Irene Gösler. 
The results of the ligand binding blot demonstrated that the isolated field isolates are able to 
bind the artificial receptor (MBP-V33333) weakly. When taking into account the in-silico 
predicted binding affinities, this ligand binding result contradicts the in-silico result. We also 
checked their abilities to infect cells lacking ICAM (RD cells). Notably all two field isolates 
were able to infect RD cells. Another important observation was that they grow equally well 
in RD and HeLa cells. Compared to the closely related (according to the VP1 sequence) 
minor group virus HRV1A, the viruses had a much longer infection time.  We conclude that 
the two investigated field isolates do not use ICAM-1 as a receptor for cell entry and are 
therefore no major group viruses. Also we can say that a possible reason for the slow infection 
is that they do not efficiently bind the cellular receptor(s).  
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6. Mutational analysis of a major group human rhinovirus.  
 
For the following experiments HRV14, the most extensively studied major group virus, was 
used. HRV14 belongs to the subgenus HRV-B. All B-types use ICAM-1 for cell entry while 
the small group of minor group viruses belong exclusively to the subgenus HRV-A. Another 
reason why we chose HRV14 was that it´s 3D structure is available [62]. Also, a full-length c-
DNA clone of HRV14 in a vector with a T7 promoter is available [29,63]. This plasmid can 
be used for site directed mutagenesis; because of the T7 promoter, infectious RNA can be 
easily produced via in-vitro RNA transcription. The goal of this part of the project was it to 
replace one of the 3 VP1 surface loops with that present in HRV2. The loops of VP1, building 
a star-shaped dome around the 5-fold axis of the virion, are called BC, DE and HI loop. The 
BC loop connects the second (B) with the third (C) strand within the typical ß-barrel jelly-roll 
structure of VP1. In the case of the DE loop, strands D and E are connected.  
For our experiments we picked the VP1 surface loop that contributes most to the receptor 
interaction; it connects the H-strand with the I-strand, and is therefore called HI-loop. When 
sequence alignments of all minor group viruses are taken into account, one single lysine 
residue within the HI-loop (K224 in HRV2) is strictly conserved. This lysine makes ionic 
interactions with an acidic cluster that is present in the ligand binding repeats of VLDLR. Ten 
members of the major group of HRVs also possess this strictly conserved lysine at an 
equivalent position in the middle of the HI loop. These latter HRVs infect cells via ICAM-1 
and cannot use LDLR. 
To obtain information about the structural basis of LDLR-binding we mutated the HI-loop of 
HRV14 in 2 different ways. From a structural point of view the HI-loops of HRV14 and 
HRV2 do not differ much from each other. However four amino-acid residues are different in 
the HI loops of HRV2 and HRV14 (Fig. 36). Once the mutated viruses are produced, their 
ability to bind LDLR can be checked via challenge of cells lacking endogenous ICAM-1 (e.g. 
human rhabdomyosarcoma cells) and testing for infectivity.  
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Figure 37. Left: Comparison of the restriction patterns via agrosegel-electrophoresis [1%] of the HRV14wt 
plasmid (HRV14-as3f WT) and the HRV14_HI2 plasmid after single-digestion with Acc65I (NEB) and double-
digestion with KpnI/AvrII (NEB). Right: Agarose gel-electrophoresis [1%] of 1µg in-vitro transcribed RNA of 
HRV14 wt and HRV14_HI2.  
6.2 In­vitro transcription of HRV14_HI2 RNA and transfection of HeLa cells. 
For obtaining viral RNA that carries the desired mutation of the HI loop, the Ambion™ T7   
in-vitro transcription kit was used. The in-vitro transcribed RNA was precipitated and its 
concentration was determined. The size of the RNA transcript was checked via agarose gel 
electrophoresis and compared to wild-type HRV14 RNA. No significant difference in the size 
of the transcripts was observed (Fig. 37, right panel). HeLa cells grown in 6 well plates were 
transfected with HRV14_HI2 RNA using magnetic bead assisted transfection (Matra). 
Unfortunately, transfection with HRV14_HI RNA did not result in infection-related cell 
death. Whereas a transfection of HRV14 WT RNA, that was used as a control resulted in 
CPE. Therefore, we had to find out whether the chimeric virus could eventually only 
accomplish one infection cycle. According to the work of Lee and colleagues [63] such virus 
can be identified via radiolabeling followed by SDS-PAGE and autoradiography. The 
procedure was performed as described in [63]. After the [35S]-methionine/cysteine was added 
the infected cells were incubated for 24 h at 34°C. The radiolabelled viruses were pelleted via 
ultracentrifuation (70,000 rpm; 2 h). An aliquot of the dissolved virus particles was mixed 
with reducing SDS-buffer. The samples were heated to 95°C for 5 min and applied on a 15 % 
polyacrylamide gel. After separation of the proteins the gel was dried and exposed to a 
radiosensitive film (24h). 
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Figure 38: left 32S radiolabelled virus samples. Samples were treated with reducing sample buffer and heated for 
5 min at 95°C. ; right: Immune precipitated virus samples applied on a 15 % polyacrylamide gel under reducing 
conditions.  
SDS-PAGE showed that a high virus concentration was required to see characteristic virus  
bands; the [35S]-labeling only worked well when seed virus was used. This was the case for 
HRV2 and HRV14 (108 TCID50). In samples transfected with the RNA no host protein shutoff 
was seen (left panel). To enrich the labeled virus particles, immune-precipitation was 
performed using α-HRV14 (rabbit) serum and staphylococcus aureus cells. 
6.3 Immunoprecipitation of [35S] labeled samples 
Immune precipitation was performed using Staphylococcus aureus cells that were incubated 
with α-HRV14 (rabbit) serum. The Staphylococcus aureus cells with bound antibodies 
against HRV14 were washed twice and mixed with the radiolabelled virus samples. During 
incubation for 1h at RT the virus particles are bound by the antibody. Via centrifugation in an 
eppendorf centrifuge the   S. aureus cells-antibody-virus particle complexes were separated 
from the non virus particles.  The mixture was washed 3 times with RIPA buffer. After adding 
reducing SDS-buffer the samples were heated for 5 min to 95°C and applied on a 
polyacrylamidgel. Following the separation of the virus proteins via PAGE the gel was dried 
and exposed to a radiosensitive film.  
With immuneprecipitation the radiolabelled virus particles were enriched. The typical bands 
representing the 3 structural proteins (VP1, VP2, VP3) were only detected in the wildtype 
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HR14 sample that was treated in the same way as the HRV14_HI chimera (Fig.38 right 
panel). This experiment demonstrated that the created HI-loop chimera of HRV14 is not 
infective.  
 
6.4 PCR mutagenesis “quick change” 
 
As the initially created chimeric virus seems to be non-infectious, we came to the conclusion 
that most probably additional mutations introduced by the polymerase during PCR 
amplification are the reason for the non-infectiveness. Excluding that the polymerase 
introduces to many errors, we used a polymerase with a higher fidelity. 
The following experiments were carried out adhering to the protocol of “quick-change” 
without using the commercially available kit. In this method, 2 primers with exactly the same 
length are used. The part of the primer that carries the mismatch is located in the middle of the 
primer, flanked by 10-16 bases that are fully complementary to the template sequence. 
Compared to the method that was used before, the PCR reactions end up in a circular plasmid. 
There is no necessity for using phosphorylated primers and also the PCR subsequent ligation 
can be omitted. Also, a different PCR machine and a different DNA-polymerase were used; 
instead of Pfu (Promega®) the Phusion® (NEB®) polymerase. The performance of the 
Phusion® polymerase with respect to fidelity and speed is much better than that of Pfu. 
By using this method, it was possible to create 2 different HRV14_HI chimeras. One named 
HRV14_K, which differs only in one amino acid from the wt sequence. The wildtype 
possesses, at position 3 in the HI loop, a histidine. The codon for the histidine (CAT) was 
changed into AAA, which is the codon for lysine. (Fig.39) The other HI loop chimera was 
again HRV14_HI2.  
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Figure 39: DNA and amino acid sequences of the 2 chimeric rhinoviruses in comparison to the HRV14 wt. The 
chimeric viruses only differ in this sequence, the rest of the sequence is identical to the wt HRV14 sequence. 
 
6.5 RNA transcription and transfection of Hela cells. 
The mutated plasmids were linearized and in-vitro transcribed as described above. Virus RNA 
was precipitated with LiCl2. The concentration of the RNA was determined and the size was 
verified on an agarose gel. As both were similar to that of the wt RNA it could be directly 
used for transfecting HeLa cells grown to 80% confluence by using Lipofectamine2000. After 
2 days the cells were found to be lysed.  
6.6 Screening the chimeric viruses via RT­PCR 
Before the chimeric viruses were used for infection of RD cells, the loop region had to be 
sequenced, assuring that the introduced mutations were present in the viral RNA. To 
accomplish sequencing of the HI loop region of viral RNA, it first has to be transcribed into 
cDNA and amplified via PCR. Before reverse transcribing the viral RNA, the virus has to be 
separated from cell-debris and infection-medium via centrifugation and harvested via ultra-
centrifugation. The virus pellet was dissolved in Tris-buffer (pH 8.5) and a 1 µl aliquot was 
taken for reverse transcription. The samples of the subsequent PCR reaction were sequenced 
confirming the correct introduction of a lysine in the RNA of HRV14_K; no mutation was 
detected in the RNA of HRV14_HI2. The loop sequence was identical to the wt sequence. 
However, sequencing of the HRV14_HI2 RNA that was used for transfection revealed that 
the sequence of the HI loop is mutated. To exclude that a contamination with wt HRV14 was 
responsible for this observation we repeated the transfection in HeLa and in RD-ICAM cells. 
In the virus samples of theses transfections, again no mutation in the HI loop sequence was 
detected. This virus was thus not further considered.  
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6.7 Infection assay 
The goal of this assay was it to detect eventual differences in replication of HRV14_K and wt 
HRV14 upon infecting RD and RD-ICAM cells. The RD (human embryo 
rhabdomyosarcoma) cell line does not express ICAM-1. According to the hypothesis that a 
lysine at position 3 in the HI loop is one of the key players for the interaction with LDLR-
family members, the chimeric rhinovirus HRV14_K might exhibit some, although low, 
affinity for LDL-receptors. However, it is not likely that HRV14_K can infect without using 
ICAM-1 as a receptor for cell entry. Infectivity of HRV14_K was compared to that of wt 
HRV14 in RD-ICAM cells. These cells are stably transfected to express human ICAM-1. 
Because of this they can be infected by minor group and major group rhinoviruses. The 80% 
confluent cell layers were incubated with serial dilutions of the supernatant of HRV14_K and 
HRV14 wt infected cells at 34°C for 3 days. Surviving cells were determined by crystal-violet 
staining (Fig. 40). 
 
Figure 40: Result of the infectivity assay in RD and RD ICAM cells. The upper 2 rows were infected with 
HRV14_K supernatant in serial dilutions. The lower 2 rows were infected with HRV14 wt supernatant at the 
same dilutions.    
As expected, no significant difference in infectivity between wt and HRV14_K was observed.  
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7. Discussion: 
 
Bioinformatics: 
The goal of this project was to find an easy automatable bioinformatic approach that is able 
from the basis of VP1 sequence data, to distinguish between major and minor group HRV´s. 
Fortunately we found such a method that could distinguish between minor group and K-type 
viruses in silico.  
The best result was obtained from the Fastcontact 2.0 web server. With this method it was 
possible to classify more than 80% of all minor group rhinoviruses correctly. With some 
improvements, i.e the correction of the not meaningfully cystein interactions of the receptor, 
the method was able to classify all minor group viruses correctly. As expected, the 
rhinoviruses with the second highest affinity to VLDLR, is the group of K-type viruses. The 
predictive power of the method is very good nevertheless the calculated affinity values are 
certainly not correct.  The absolute values of HRV2 are far from those measured by 
fluorescence correlation spectroscopy [54]. Furthermore the highest affinity was calculated 
for HRV1A however, this contradicts the weak inhibition of infection with MBP-V33333 
after 72 h of incubation, described in the publication of Verdaguer [33]. The K-type viruses 
that are described as weak binder of MBP-V33333 [Khan et al., unpulished], as HRV8 and 
HRV18 have calculated affinities that are close to the separation line. Having found a suitable 
method for affinity calculation, we also wanted to analyze the contribution of the involved 
residues of the different viruses. The primary goal was to find different conserved binding 
patterns in minor group and K-type viruses. Summarizing the results of the heat map and the 
bar diagram representations, we can say that there are no such defined patterns neither in K-
types nor in minor group viruses. The same residues were found to contribute to binding in 
minor and K-type viruses, with only marginal differences. Nevertheless, the binding affinities 
to six receptor residues were higher for minor group viruses than for K-type viruses 
(statistically confirmed). Despite, all affinity predictions were based on models but not on 
experimentally determined structures the obtained results were remarkably good.  
All calculations were based on the 3D structure of the HRV2 in complex with V3 of VLDLR. 
However VLDLR most probably does not play an important role for minor group virus cell 
entry, because it is not highly expressed in nasal epithelial cells, the primary site of rhinovirus 
infections.   
77 
 
We expected that the separation of minor and major group viruses based on the calculated 
affinities when using LDLR would be more clear cut.  The results using the natural receptor 
(L5 of LDLR) substantially differ from the initial results. However the separation of minor 
and K-type viruses was much less clear, this may also be due to the use of two models (VP1-
model and receptor model) that were superimposed to the HRV2/V3 structure.  
All known minor group viruses share the same function as they all bind LDLR for cell entry. 
When we inspect the predicted binding affinities of all 12 minor group viruses to the ligand 
binding repeat 5 of human LDLR, it contradicts the known binding abilities of this virus 
group. A plausible reason, why this method could not reliable classify human rhinoviruses 
when the human LDLR (L5) was used as a receptor in the caculations is that this method was 
initially designed for predicting binding affinities to the V3 of VLDLR. The coordinates and 
exact orientation of the V3 were obtained from the determined structure in complex with 
HRV2 [33]. Down to the present day, no structure of a minor group virus in complex with a 
LDLR ligand repeat was published. Accordingly, we cannot be certain whether the orientation 
of virus and receptor corresponds to that adapted in real life. Furthermore, we cannot exclude 
that different minor group viruses use different ligand binding repeats for cell entry, or simply 
use ligand binding repeats of LRP.  
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 Analysis of the unclassified field isolates. 
This experiment was a great opportunity for evaluating our bioinformatic approach. 
Regardless of the close relationship between the field isolates to HRV1A, the 2 analyzed 
isolated types had much lower predicted affinities. Compared to affinities calculated for minor 
group viruses their affinities were much lower, suggesting that they probably cannot use 
LDLR. In this case the affinity calculation could not predict the right receptor specificity, 
since an infectivity test revealed that these viruses are able to replicate in cells without    
ICAM-1. In addition, a ligand binding blot showed that these viruses are able to weakly bind 
MBP-V33333.  
To assess whether the arginine was the reason for decreased affinity, it was mutated to lysine 
in-silico and binding affinities were again calculated. The predicted binding affinities of this 
improved sequence (with the lysine) were approximately the same as the affinity of HRV2 
(data not shown). This result suggests that the arginine residue within the HI-loop cannot 
strongly interact with the V3 of VLDLR, whereas a lysine residue can. We hypothesize that in 
contrast to K-type viruses the analyzed field isolates are able to uncoat at endosomal pH, and 
therefore are able to infect RD cells. 
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Mutagenesis: 
The goal of this project was the creation of a HRV14 HI-loop chimeric virus. The wildtype 
HRV14 HI-loop sequence should be changed into the sequence of HRV2. At the end a 
HRV14 (major group) with the HI-loop sequence of HRV2 (minor group) should be 
established. The HI-loop is the most involved surface loop in the LDLR-rhinovirus 
interaction. The idea was that such a chimeric major group virus would have a greater affinity 
to the LDL receptor, a receptor that is not used by major group viruses. As the location of the 
mutations is structurally far away from the canyon, the ICAM-1 binding part of the virus 
capsid, it should not alter the binding to ICAM-1. 
Since, no suitable restriction sites are present in the HRV14 genome that would allow an easy 
exchange of the HI-loop we had to use methods of site directed mutagenesis for the 
introduction of mutations. Generally larger plasmids, as the plasmid we were using (~10kb) 
are not easy to mutate. A general property of human rhinoviruses makes it even harder to 
mutate rhinovirus sequences, regarding the low G+C content (HRV14 VP1 36%). [11] The 
manuals of site directed mutagenesis kit always recommend the use of primers that have 
about 40% G-C content in their sequence. At first we used the method of “round the horn” 
site directed mutagenesis. With this method it was possible to introduce the full HI-loop of 
HRV2 into the sequence of HRV14 in one round of PCR amplification. The successfully 
introduced loop sequence was confirmed via DNA sequencing.  
However, the RNA obtained upon transcription did not result in CPE in the transfected HeLa 
cells. Avoiding sequencing of the full rhinovirus genome, we decided to investigate whether 
the mutated virus RNA is able to at least initiate one round of infection. As this can be 
excluded the reason for the lack of replication is most probably correlated with polymerase 
induced errors in the RNA sequence.  To overcome this problem a new method of site 
directed mutagenesis was carried out. With this method (“quick-change”), which utilizes a 
polymerase with higher accuracy, it was also possible to create the HRV14_HI2 chimera. At 
first the created chimera seems to be infective, but sequencing of RT PCR amplified virus 
cDNA revealed that the mutations cannot be found in virus samples. However, HRV14_K, a 
chimeric virus with only a slightly changed HI-loop that was also amplified with the “quick-
change” method, was also tested for infectivity. It turned out that this chimeric virus was able 
to infect HeLa cells. The correct introduction of the mutation was confirmed via sequencing 
of the RT-PCR amplified viral cDNA. According to the result of an infectivity experiment, 
where RD and RD ICAM cells were challenged with HRV14_K and HRV14 wt viruses, no 
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significant differences between HRV14_K and HRV14 wt regarding infectivity could be 
observed. 
Regardless of the used method, the chimeric viruses with the HRV2 HI-loop were not 
infective. It appears unlikely that the four changed amino-acid residues in the HI-loop are 
responsible for the loss of infectivity. This approach was designed to exchange residues that 
are important for interaction with LDL receptors, without changing the binding site (canyon) 
for the native receptor of major group rhinoviruses (ICAM-1). Therefore it can be excluded 
that mutation in the HI-loop alters the ICAM-1 binding site.  
An explanation for the detection of wt sequences after transfection with HRV14_HI2 RNA 
could be that a non-homogenous RNA fraction of HRV14_HI2 was used for transfection.  
This in-homogenous RNA most probably contains traces of wt RNA that are not detected 
during sequencing. Excluding a real back-mutation of the HI-loop sequence after one round of 
infection suggests that the HRV14_HI2 clone is non-infectious. Otherwise the cDNA 
sequencing would have confirmed the mutation. Nevertheless the clone of HRV14_K is 
infective. This artificial K-Type does not differ from the HRV14 wildtype regarding 
infectivity, but it is an interesting object for later studies. Normal K-Type viruses are A class 
viruses and some of them are weak binders of MBP-V33333 (HRV8, HRV24, HRV18). This 
artificial one could help to answer the question whether B class viruses with a lysine in the HI 
loop can also bind MBP-V33333. The HRV14_K clone can be used for continuing with 
further mutagenesis experiments.  
As a conclusion we can say that site directed mutagenesis can be used for mutating rhinovirus 
sequences. The reasons why the chimeric rhinovirus HRV14_HI2 is not infectious remains 
unclear.  
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